Evidence map›Paper›PMID 39863708›Full record

ArticleEye (London, England)2025

Analysis of quantitative OCT and SS-OCTA metrics three months after initiation of intravitreal faricimab for treatment-recalcitrant neovascular AMD.

Arnold Nadel, Michael Drakopoulos, Harnaina K Bains, Avram Bar-Meir, Alessandro Marchese, Alice T Lyon, Rukhsana G Mirza

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Arnold NadelDepartment of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Michael DrakopoulosDepartment of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.ORCID http://orcid.org/0000-0001-8219-5136
Harnaina K BainsDepartment of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Avram Bar-MeirDepartment of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Alessandro MarcheseDepartment of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Alice T LyonDepartment of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Rukhsana G MirzaDepartment of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. r-mirza@northwestern.edu.ORCID http://orcid.org/0000-0003-1351-5874

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo utilize optical coherence tomography (OCT) and SS-OCT angiography (SS-OCTA) for quantifying morphological changes seen in eyes with recalcitrant neovascular age-related macular degeneration (nAMD) transitioned to intravitreal faricimab injections during the manufacturer's recommended induction phase of treatment.

methodsFifty-four treatment-recalcitrant patients (60 eyes) were recruited. OCT and SS-OCTA images were obtained at 0 and 3 months. Best-corrected visual acuity (BCVA), OCT, pigment epithelial detachment (PED), and macular neovascularization (MNV) parameters were analyzed at baseline and 3 months.

resultsThirty-two patients (38 eyes) were included in the baseline OCT characteristic analysis, 29 patients (35 eyes) in the MNV analysis, and 18 patients (21 eyes) in the PED analysis. Significant decreases in PED parameters were observed, including PED volume (mean decrease of 0.0592 mm

conclusionsIn recalcitrant nAMD patients who were transitioned to faricimab, patients maintained their vision while significant improvements in OCT PED and SS-OCTA MNV parameters were seen during the induction phase.

Indexed as

Angiogenesis InhibitorsTomography, Optical CoherenceWet Macular DegenerationAgedAged, 80 and overAntibodies, BispecificFemaleFluorescein AngiographyFollow-Up StudiesHumansIntravitreal InjectionsMaleMiddle AgedProspective StudiesVascular Endothelial Growth Factor AVisual AcuityAngiogenesis InhibitorsAntibodies, BispecificfaricimabVascular Endothelial Growth Factor A

Identifiers

PMID39863708
PMCPMC12043917

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.